{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:44:55Z","timestamp":1782711895749,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01148-9","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:02:38Z","timestamp":1782709358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of lipoprotein glomerulopathy in which complete remission was achieved by pemafibrate therapy"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3041-5182","authenticated-orcid":false,"given":"Chika","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Misaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1148_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2005.10.017","volume":"47","author":"T Saito","year":"2006","unstructured":"Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199\u2013211.","journal-title":"Am J Kidney Dis"},{"key":"1148_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0272-6386(89)80134-9","volume":"13","author":"T Saito","year":"1989","unstructured":"Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148\u201353.","journal-title":"Am J Kidney Dis"},{"key":"1148_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.905007","volume":"9","author":"MS Li","year":"2022","unstructured":"Li MS, Li Y, Liu Y, Zhou XJ, Zhang H. An updated review and meta analysis of lipoprotein glomerulopathy. Front Med. 2022;9:905007.","journal-title":"Front Med"},{"issue":"5","key":"1148_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1681\/ASN.V85820","volume":"8","author":"S Oikawa","year":"1997","unstructured":"Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, et al. Apolipoprotein E sendai (arginine 145proline). J Am Soc Nephrol. 1997;8(5):820\u20133.","journal-title":"J Am Soc Nephrol"},{"key":"1148_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1523-1755.1999.00572.x","volume":"56","author":"A Matsunaga","year":"1999","unstructured":"Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421\u20137.","journal-title":"Kidney Int"},{"key":"1148_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000045511","volume":"83","author":"T Saito","year":"1999","unstructured":"Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron. 1999;83:193\u2013201.","journal-title":"Nephron"},{"key":"1148_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving global outcomes glomerular diseases work G. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1\u2013276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"key":"1148_CR8","volume":"2","author":"EM Hodson","year":"2022","unstructured":"Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022;2:CD003233.","journal-title":"Cochrane Database Syst Rev"},{"key":"1148_CR9","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/ndt\/12.11.2442","volume":"12","author":"PA Andrews","year":"1997","unstructured":"Andrews PA, O\u2019Donnell PJ, Dilly SA, Snowden SA, Bewick M. Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol Dial Transplant. 1997;12:2442\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"1148_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ekir.2018.09.020","volume":"4","author":"I Batal","year":"2019","unstructured":"Batal I, Fakhoury G, Groopman E, D\u2019Agati VD, Morris H. Unusual case of lipoprotein glomerulopathy first diagnosed in a protocol kidney allograft biopsy. Kidney Int Rep. 2019;4:350\u20134.","journal-title":"Kidney Int Rep"},{"key":"1148_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.ajt.2025.04.018","volume":"25","author":"PDM de Menezes Neves","year":"2025","unstructured":"de Menezes Neves PDM, Mansur J, Moyses-Neto M, Rohde RW, Poli-de-Figueiredo CE, Araujo SA, et al. Post-transplantat recurrence of lipoprotein glomerulopathy: report of 4 cases and literature review. Am J Transplant. 2025;25:2017\u201322.","journal-title":"Am J Transplant"},{"key":"1148_CR12","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/S0041-1345(97)00409-0","volume":"29","author":"G Mourad","year":"1997","unstructured":"Mourad G, Cristol JP, Turc-Baron C, Djamali A. Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. Transplant Proc. 1997;29:2376.","journal-title":"Transplant Proc"},{"key":"1148_CR13","doi-asserted-by":"publisher","first-page":"9311","DOI":"10.1186\/1752-1947-3-9311","volume":"3","author":"G Russi","year":"2009","unstructured":"Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-induced extracorporeal lipoprotein precipitation system): a case report. J Med Case Rep. 2009;3:9311.","journal-title":"J Med Case Rep"},{"key":"1148_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ndt\/gfn555","volume":"24","author":"Z Xin","year":"2009","unstructured":"Xin Z, Zhihong L, Shijun L, Jinfeng Z, Huiping C, Caihong Z, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant. 2009;24:864\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1148_CR15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/102490790801500111","volume":"15","author":"CY Cheung","year":"2009","unstructured":"Cheung CY, Chan AO, Chan YH, Lee KC, Chan GP, Lau GT, et al. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J. 2009;15:57\u201360.","journal-title":"Hong Kong Med J"},{"key":"1148_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5414\/CN106876","volume":"78","author":"MT Liao","year":"2012","unstructured":"Liao MT, Tsai IJ, Cheng HT, Lin WC, Chang YW, Lin YH, et al. A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy. Clin Nephrol. 2012;78:237\u201340.","journal-title":"Clin Nephrol"},{"key":"1148_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacl.2018.12.004","volume":"13","author":"DTW Lui","year":"2019","unstructured":"Lui DTW, Lee ACH, Yap DYH, Chan GSW, Tan KCB. A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy. J Clin Lipidol. 2019;13:251\u20133.","journal-title":"J Clin Lipidol"},{"key":"1148_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ki.2013.335","volume":"85","author":"Z Hu","year":"2014","unstructured":"Hu Z, Huang S, Wu Y, Liu Y, Liu X, Su D, et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int. 2014;85:416\u201324.","journal-title":"Kidney Int"},{"key":"1148_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/ajkd.2003.50016","volume":"41","author":"N Ieiri","year":"2003","unstructured":"Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis. 2003;41:244\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1148_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0021-9150(03)00194-1","volume":"169","author":"T Arai","year":"2003","unstructured":"Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis. 2003;169:293\u20139.","journal-title":"Atherosclerosis"},{"key":"1148_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10157-009-0207-1","volume":"13","author":"A Matsunaga","year":"2009","unstructured":"Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol. 2009;13:659\u201362.","journal-title":"Clin Exp Nephrol"},{"key":"1148_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s13730-016-0214-5","volume":"5","author":"R Usui","year":"2016","unstructured":"Usui R, Takahashi M, Nitta K, Koike M. Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation. CEN Case Rep. 2016;5:148\u201353.","journal-title":"CEN Case Rep"},{"key":"1148_CR23","doi-asserted-by":"crossref","unstructured":"Wu H, Yang Y, Hu Z. The novel apolipoprotein E mutation ApoE Chengdu (c.518T>C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy. J Atheroscler Thromb. 2018; 25:733\u201340.","DOI":"10.5551\/jat.41996"},{"key":"1148_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/IJNRD.S364890","volume":"15","author":"JA Ting","year":"2022","unstructured":"Ting JA, McRae SA, Schwartz D, Barbour SJ, Riazy M. Lipoprotein glomerulopathy, first case report from Canada. Int J Nephrol Renovasc Dis. 2022;15:207\u201314.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"1148_CR25","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.2169\/internalmedicine.0834-22","volume":"62","author":"H Tanimizu","year":"2023","unstructured":"Tanimizu H, Hara R, Sekine A, Inoue N, Hasegawa E, Tanaka K, et al. Apolipoprotein E-associated lipoprotein glomerulo-tubulopathy. Intern Med. 2023;62:2209\u201314.","journal-title":"Intern Med"},{"key":"1148_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13730-024-00861-7","volume":"13","author":"K Vala","year":"2024","unstructured":"Vala K, Shah K, Kapadia S, Khandelwal M, Jojera A, Soni S, et al. Lipoprotein glomerulopathy: a rare cause of steroid-resistant nephrotic syndrome in a child. CEN Case Rep. 2024;13:403\u20137.","journal-title":"CEN Case Rep"},{"key":"1148_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12882-024-03612-z","volume":"25","author":"J Kato","year":"2024","unstructured":"Kato J, Okonogi H, Kanzaki G, Katsumata H, Nakada Y, Sagasaki M, et al. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report. BMC Nephrol. 2024;25:171.","journal-title":"BMC Nephrol"},{"key":"1148_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1177\/10668969241228298","volume":"32","author":"N Shaker","year":"2024","unstructured":"Shaker N, Ben Musa R, Shaker N, Nasir H, Kamran TE, Poombal F, et al. Lipoprotein glomerulopathy with complete resolution with fenofibrate: report of first case from Pakistan. Int J Surg Pathol. 2024;32:1404\u20138.","journal-title":"Int J Surg Pathol"},{"key":"1148_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13730-024-00920-z","volume":"14","author":"A Yokochi","year":"2025","unstructured":"Yokochi A, Matsunaga A, Kanemoto K, Tominaga N, Uda S, Saito T. Lipoprotein glomerulopathy with a novel apolipoprotein E variant, APOE Kanto (Asp 151dup). CEN Case Rep. 2025;14:162\u20136.","journal-title":"CEN Case Rep"},{"key":"1148_CR30","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088\u201393.","journal-title":"Circulation"},{"key":"1148_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARalpha modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22:5.","journal-title":"Curr Atheroscler Rep"},{"key":"1148_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102696","author":"EV Fuior","year":"2023","unstructured":"Fuior EV, Zvintzou E, Filippatos T, Giannatou K, Mparnia V, Simionescu M, et al. Peroxisome proliferator-activated receptor \u03b1 in lipoprotein metabolism and atherosclerotic cardiovascular disease. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11102696.","journal-title":"Biomedicines"},{"key":"1148_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16:124.","journal-title":"Cardiovasc Diabetol"},{"key":"1148_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5551\/jat.48918","volume":"26","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPARalpha modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26:389\u2013402.","journal-title":"J Atheroscler Thromb"},{"key":"1148_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and Low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25:521\u201338.","journal-title":"J Atheroscler Thromb"},{"key":"1148_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121590","volume":"321","author":"Y Horinouchi","year":"2023","unstructured":"Horinouchi Y, Murashima Y, Yamada Y, Yoshioka S, Fukushima K, Kure T, et al. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci. 2023;321:121590.","journal-title":"Life Sci"},{"key":"1148_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225682","author":"Y Sasaki","year":"2019","unstructured":"Sasaki Y, Raza-Iqbal S, Tanaka T, Murakami K, Anai M, Osawa T, et al. Gene expression profiles induced by a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1) pemafibrate. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20225682.","journal-title":"Int J Mol Sci"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01148-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:02:46Z","timestamp":1782709366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01148-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01148-9","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient consented to reporting of her case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"112"}}